How to Prepare Technical Documentation for Overseas Registration of Medical Imaging Devices

Key Summary

A practical guide for medical imaging device manufacturers, covering regulatory classification, reusable evidence, localisation, common pitfalls, and a preparation checklist for markets such as GHWP member states, Southeast Asia, the Middle East, and Latin America.

Published: 2026-08-12 17:35 | Updated: 2026-08-12 17:35

This FAQ addresses key issues that medical device companies must consider when preparing technical documentation for overseas registration of imaging equipment. It focuses on reducing rework, shortening registration timelines, and ensuring compliance across multiple markets.

Key Summary

To organise technical files for overseas registration of medical imaging devices, a company should first determine whether the target country regulates the product as a medical device. Next, confirm the risk classification and the applicable registration pathway and applicant entity. The company should then assess whether existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation can be reused, and plan localised adaptation for GHWP member states, Southeast Asia, the Middle East, Latin America, and other markets. The technical file must cover product specifications, performance verification, risk management, clinical evaluation or evidence, labelling and instructions for use, local agent or authorised representative, and post-market maintenance requirements. Common risks include incorrect risk classification, insufficient clinical evidence, labelling that is not localised, unclear agent responsibilities, lack of control over certificates, and delays in changes and renewals. Companies should establish a core documentation repository, manage reusable evidence and localised files in separate layers, and confirm local regulatory and language requirements early to avoid duplicative preparation and deficiency responses in each country.

For Chinese medical device manufacturers, a robust approach is to first perform product classification and documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Registration in a target market typically affects not only technical files but also authorised representation, importer cooperation, label language, quality system evidence, and ongoing change control. If the project is driven solely by a checklist of required documents, deficiencies and rework often arise in model coverage, consistency of the evidence chain, labelling claims, and certificate control. AIMEILI recommends that companies plan imaging device registrations as part of a broader GHWP and multi-country market access strategy, using one set of reusable core technical documents to support localisation in different markets rather than recreating files from scratch for every country.

Applicable Scenarios and Core Issues

Overseas registration of medical imaging devices covers CT, MRI, ultrasound, X-ray, endoscopy, molecular imaging, and other products. Regulatory frameworks, risk classifications, technical documentation formats, and language requirements vary significantly among countries. Companies often discover only after starting registration that the documentation is incomplete, the format is wrong, or the evidence level does not match local expectations, leading to project delays and higher costs.

This article is intended for manufacturers, CROs, and regulatory affairs professionals working on imaging device registration in GHWP member states, Southeast Asia, the Middle East, Latin America, and other regions. The central question is: how should technical documentation be prepared to minimise rework, shorten approval timelines, and lower compliance risk?

Preparing technical files is not simply translating NMPA or CE submission dossiers. It requires building a traceable, reusable, and localisable evidence chain. Companies must first understand the registration logic of the target country, then take stock of existing documentation, and finally complete a gap analysis and document adaptation.

Registration Decision Logic

Step 1: Confirm Regulatory Scope

Determine whether the product falls within the target country's medical device regulatory scope. Some imaging software, standalone diagnostic workstations, or accessories may or may not be classified as medical devices. Confirm this through local regulations or consultation with a local agent.

Step 2: Determine Risk Classification and Registration Pathway

Imaging devices are usually classified into Class I, II, or III according to increasing risk, with corresponding registration, notification, or filing pathways. Classification determines the depth of technical documentation, clinical evidence requirements, and review timelines.

Step 3: Assess Reusable Existing Documentation

NMPA registration files, CE technical documentation, FDA 510(k) or PMA files, ISO 13485, and MDSAP certificates are valuable starting points. However, each country has its own format requirements and additional evidence expectations, so direct full-scale copying is not acceptable.

Step 4: Identify Local Agent or Authorised Representative

Most countries require foreign applicants to appoint a local entity responsible for communication with regulatory authorities, certificate receipt, adverse event handling, and post-market surveillance. The qualification and stability of the agent directly affect certificate control and future changes.

Step 5: Plan Post-Market Maintenance

This includes certificate validity, renewal cycles, change notifications, annual reports, adverse event reporting, and recall obligations. These requirements should be integrated into the technical file preparation process from the beginning to avoid compromising certificate validity.

Documentation and Evidence

Technical files for overseas registration of imaging devices typically include: product description, intended use, technical specifications, manufacturing information, performance verification, risk management, software description and validation, electrical safety, electromagnetic compatibility, biological evaluation, clinical evaluation or clinical data, labelling and instructions, and sterilisation information (if applicable).

The technical documentation index should be compiled according to the target country's requirements. For example, most GHWP member states reference IMDRF or their own national guidelines; some Southeast Asian countries accept the common documentation structure of the ASEAN Medical Device Directive; the Middle East and Latin America have their own specific requirements.

Key performance verification evidence includes: image quality, dose, accuracy, repeatability, stability, environmental testing, and transport testing. Test methods, acceptance criteria, test reports, and traceability to raw data must be provided.

Risk management documentation should be based on ISO 14971 and cover the full lifecycle from design to post-market. Clear risk acceptability criteria must be defined and a risk management report provided. If the existing report is based on a CE version, verify whether it meets the target country's safety standards and regulatory requirements.

Clinical evaluation or clinical evidence is the most challenging part of imaging device registration. High-risk devices require clinical data; low- and medium-risk devices may rely on equivalence comparison and literature-based arguments. Companies should determine early whether local clinical trials are needed and whether overseas clinical data will be accepted.

Labelling and instructions for use must be localised. This includes language, units of measurement, warnings, symbols, manufacturer information, agent information, and after-sales contacts. The instructions must comply with local medical device labelling regulations and cannot simply be an English version.

Software-based imaging devices require additional submission of a software description document, cybersecurity statement, algorithm validation report, and version management files. Some countries classify software separately or impose extra requirements; early confirmation is essential.

Quality system certificates and quality management documents are part of the technical file. Most countries require an ISO 13485 certificate, some accept MDSAP, and others require a local audit or on-site inspection. Verify the certificate's scope, validity, and language requirements.

Common Errors

Incorrect risk classification: Preparing a Class III device as Class II results in insufficient documentation depth or changed review expectations.
Direct translation of entire dossiers: Local regulatory differences and special formats are ignored.
Insufficient clinical evidence: Overseas clinical data are used without analysis of applicability to the local population or context.
Non-localised labelling: Missing target-country language, warning statements, or agent information.
Risk management report not updated to target-country standards.
Incomplete software evidence: Lacking software description, cybersecurity statement, or version traceability.
Unclear local agent responsibilities: Leading to communication delays or loss of certificate control.
Neglect of post-market obligations: Renewal, change notification, and adverse event reporting are not planned.

Company Preparation Checklist

Identify the target country, product classification, and registration pathway; document the classification basis.
Take stock of existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation; create a reusable evidence inventory.
Prepare a target-country technical document index mapping each item to corresponding evidence and reports.
Complete key strategies for risk management, electrical safety, electromagnetic compatibility, and biological evaluation.
Determine the clinical evaluation pathway; initiate a clinical trial or collect literature evidence where necessary.
Prepare localised labels and instructions for use; confirm language, format, and agent information.
Appoint or tender a local agent with a clear authorisation agreement and change-handling process.
Establish a post-market surveillance system covering adverse events, complaints, and update reports.

AIMEILI Regulatory Interpretation and Business Impact

The most frequent mistakes in overseas registration of imaging devices are misjudging risk classification and underestimating the depth of clinical evidence required. Many companies assume that holding a CE certificate or a domestic registration certificate means the documentation is universally applicable, but many countries have their own classification directories and review considerations. In the early phase of a project, spend two weeks on regulatory research and gap analysis of the target country rather than starting translation immediately.

AIMEILI recommends performing a reusability assessment first, dividing documentation into three categories. The first category is common technical files, such as product description, principle of operation, performance data, and risk management framework, which can be reused across multiple countries. The second category is files that require localisation, such as labels, instructions, local agent information, and report formats. The third category is files that must be newly created, such as local clinical evaluations or specific regulatory conformity statements.

Control over the local agent and certificates is critical. Many companies overlook the long-term service capability of the agent; the certificate ends up controlled by the agent, and changes and renewals become dependent on them. Companies should clearly define in the authorisation agreement the ownership of certificates, obligations for document handover, and time limits for change services.

For multi-country registration, do not start from scratch for each country. Establish a core technical documentation library first, then generate country-specific versions according to each market's requirements. This approach significantly reduces duplicate work and deficiency risk. In AIMEILI's experience, companies that systematically organise their documentation can save more than 30% of redundant work and reduce review deficiencies caused by formatting and translation issues.

Common Follow-up Questions

Can existing CE technical files be used directly for overseas registration?

No. CE files are based on EU regulations. Target countries may require additional classification evidence, clinical evaluation, local labelling, and agent information. Use CE files as a baseline and perform a gap analysis and localisation adjustment.

Are technical files mutually recognised among GHWP member states?

GHWP encourages regulatory harmonisation, but national registration procedures and document requirements still differ. Some countries may accept a registration certificate or review report from another country, but they usually still require locally formatted technical documents. It is recommended to leverage reusable test reports and risk management data where possible.

What is the difference between a local agent and an authorised representative?

In most countries, the local agent and the authorised representative are the same role: a legal entity in the target country designated by the overseas applicant. The difference lies in the emphasis on legal authorisation versus certificate-holding responsibility. Confirm the target country's definition to avoid mismanagement of certificate control.

Need a registration pathway assessment?

Send product type, intended use, target countries and existing certificates. AIMEILI can help evaluate registration pathway, documentation gaps and compliance risks.

Contact AIMEILI